Live Multicellular Tumor Spheroid Models For High-Content Imaging and Screening In Cancer Drug Discovery

Live Multicellular Tumor Spheroid Models For High-Content Imaging and Screening In Cancer Drug Discovery

The multi cellular tumor spheroid (MCTS) model has been used for decades with proven superiority over monolayer cell culture models at recapitulating in vivo tumor growth. Yet its use in high-throughput drug discovery has been limited, particularly with image based screening, due to practical and technical hurdles. Here we report a significant advance in utilizing live MCTS models for high-cont...

High Content Screening in Drug Discovery

The term high content screening (HCS) has become synonymous with imaging screen using automated microscopes and automated image analysis. The term was coined a little over 10 years ago, since then the technology evolved considerably and has established itself firmly in the drug discovery and development industry. Both the instruments and the software controlling the instruments and analyzing th...

Phenotypic Drug Discovery with High Content Screening

Drug discovery in its early history used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system -cells, tissue, or organisms -and asking the question, ‘Did this entity affect the phenotype?’. With the rise of molecular biology in the early 1980s and an ever more powerful genomics toolkit from the 1990s, there was a marked shift away from pheno...

Image-Based High-Content Screening in Drug Discovery

Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening

The increasing number of publications on the subject shows that nanomedicine is an attractive field for investigations aiming to considerably improve anticancer chemotherapy. Based on selective tumor targeting while sparing healthy tissue, carrier-mediated drug delivery has been expected to provide significant benefits to patients. However, despite reduced systemic toxicity, most nanodrugs appr...